Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2020. augusztus 27., csütörtök 11:10 |
Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed |
|
Jena/ Germany, 27 August, 2020 (APA/OTS) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published(1) - Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). Within the accuracy of the study, the risk of a local tumor recurrence in the breast is similar and non-breast cancer death is reduced. The TARGIT-A randomized, multi-center phase 3 study involving 2298 patients with a median patient follow-up time of 8.6 years meets the highest scientific standards. |
Globally more than 40,000 patients have already been treated, in
over 350 breast cancer centers, with the TARGIT method. "Single dose
intra-operative radiotherapy for early stage breast cancer can be a
better alternative to conventional whole breast radiotherapy for
most patients during primary tumor management " stated the principal
investigator Professor Jayant Vaidya, Professor of Surgery and
Oncology and Scientific Director at University College London when
presenting the results of the study. "These excellent results
provide real clinical justification for single intraoperative
radiation in suitable patients with early breast cancer. It is now
essential to develop the corresponding treatment guidelines as soon
as possible", added Professor Jeffrey Tobias, Professor of Oncology
at University College London and joint initiator of the TARGIT-A
study.
Positive clinical study results validate TARGIT as an option in
breast cancer treatment
The local, recurrence-free survival rate of women treated with
single dose TARGIT is non-inferior when compared with EBRT. The
mortality in the TARGIT arm was even lower because of fewer
cardio-vascular deaths.
"We are delighted with the positive results, as the ZEISS INTRABEAM
600 now represents an outstanding treatment alternative for many
patients. We are confident that the procedure can now find its way
into everyday clinical practice" said Ludwin Monz, CEO of Carl Zeiss
Meditec AG.
(1) https://www.bmj.com/content/370/bmj.m2836
TARGIT method underscored as an efficiency-oriented treatment
'This study reflects two decades of interdisciplinary clinical
research by leading radiation oncologists, surgeons, physicists and
health economists. The TARGIT-A trial has offered many breast cancer
patients a treatment that is well tolerated, effective, convenient
and highly cost efficient', summarized Professor William Small,
Professor of Radio-oncology at Loyola University, Chicago and one of
the world's leading radiation oncologists.
Contacts for the press: Petra Rettenmaier Head of Marketing Communications Visualization Carl Zeiss Meditec AG Phone: +49 7364 204-232 Email: press.meditec@zeiss.com
Contact for investors Sebastian Frericks Director of Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Email: investors.meditec@zeiss.com
www.zeiss.de/presse
Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's
leading medical technology companies and is included in the German
MDAX and TecDAX stock indices. The Company supplies innovative
technologies and application-oriented solutions designed to help
doctors improve the quality of life of their patients. The company
offers complete solutions for the diagnosis and treatment of eye
diseases - including implants and consumables. In microsurgery, the
Company provides innovative visualization solutions. With
approximately 3,230 employees worldwide, the company generated
revenue totaling €1,459.3 million in fiscal year 2018/19 (ended 30
September).
The company is headquartered in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the US, Japan, Spain and France. The Center
for Application and Research (CARIn) in Bangalore, India and the
Carl Zeiss Innovations Center for Research and Development in
Shanghai, China, strengthen the Company's presence in these rapidly
developing economies. Around 41 percent of Carl Zeiss Meditec AG
shares are in free float. The remaining approx. 59 percent are held
by Carl Zeiss AG, one of the world's leading companies in the
optical and optoelectronic industries.
For more information please visit: www.zeiss.com/med
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|